Triclabendazole

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Triclabendazole
Triclabendazole.svg
Clinical data
Trade namesFasinex, Egaten, others
AHFS/Drugs.comInternational Drug Names
Routes of
administration
by mouth
ATC code
Pharmacokinetic data
MetabolismOxidation to sulfone and sulfoxide metabolites
Elimination half-life22–24 hs
ExcretionFeces (>95%), urine (2%), milk (<1%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.127.414 Edit this at Wikidata
Chemical and physical data
FormulaC14H9Cl3N2OS
Molar mass359.658 g·mol−1
3D model (JSmol)
Melting point175 to 176 °C (347 to 349 °F)
 ☒N☑Y (what is this?)  (verify)

Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat liver flukes, specifically fascioliasis and paragonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]

Side effects are generally few, but can include abdominal pain and headaches.[1] Biliary colic may occur due to dying worms.[2] While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population.[2] It is a member of the benzimidazole family of medications for worms.[1]

Triclabendazole was approved for medical use in the United States in 2019.[3] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] For human use it can also be obtained from the World Health Organization.[2] It is also used in other animals.[5]

Chemistry[edit]

It is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin therefore preventing the polymerization of microtubules.

History[edit]

Since late 1990s, triclabendazole became available as a generic drug, as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension, was launched by Agrovet Market Animal Health in the early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched, also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat infections by Fasciola hepatica (both immature and adult liver flukes), roundworms and ectoparasites, as well.

Fasinex is a brandname for veterinary use while Egaten is a brandname for human use.

References[edit]

  1. ^ a b c d e f WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 94, 96. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  2. ^ a b c Wolfe, M. Michael; Lowe, Robert C. (2014). "Benzimidazoles". Pocket Guide to GastrointestinaI Drugs. John Wiley & Sons. p. PT173. ISBN 9781118481554. Archived from the original on 2016-12-20.
  3. ^ "Egaten (triclabendazole)" (PDF). FDA. Retrieved 18 February 2019.
  4. ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  5. ^ "Triclabendazole - Drugs.com". www.drugs.com. Archived from the original on 20 December 2016. Retrieved 10 December 2016.

Further reading[edit]